Moderna, Inc. (NASDAQ:MRNA) has announced regulatory submissions for its Respiratory Syncytial Virus (RSV) vaccine, mRNA-1345, aimed at preventing RSV-associated lower respiratory tract disease and acute respiratory disease in adults aged 60 years or older. The company has submitted marketing authorization applications to the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia, and initiated the rolling submission process for a Biologics License Application to the U.S. FDA.